Summary of some of the presentations from the session “ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension”

Study name [ref.]PopulationInterventionComparisonPrimary/secondary outcomes
Exploring efficacy and safety of oral pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) [26]Progressive fibrosing ILDPirfenidone
24 weeks
PlaceboStopped due to low recruitment; lower FVC decline in treatment arm when applying pre-specified imputation, but not without
Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD [3]Progressive fibrosing unclassifiable ILDPirfenidone
24 weeks
PlaceboPrimary end-point (FVC change by home spirometry) was not assessed due to technical problems; lower FVC decrease in treatment arm in site spirometry
Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial [25]Progressive fibrosing ILDNintedanib
52 weeks
PlaceboLower adjusted annual rate of decline in FVC (mL·year−1)
Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc) [27]Systemic sclerosisTocilizumab
48 weeks
PlaceboNo difference in change in modified Rodnan skin score; lower proportion of patients losing >10% of FVC on the treatment arm
Transbronchial lung cryobiopsy for interstitial lung disease diagnosis: results of the COLDICE Study [28]ILD requiring biopsyTransbronchial lung cryobiopsySurgical lung biopsyHigh level of agreement between both types of biopsy

IPF: idiopathic pulmonary fibrosis; ILD: interstitial lung disease; FVC: forced vital capacity.